Pfizer Inc. expects to begin testing its first maternal vaccination candidate – a vaccine against group B streptococcus – in the clinic in late 2016 or early 2017, President-Worldwide R&D Mikael Dolsten said following a briefing at the company’s New York headquarters July 21.
Pfizer Turns Vaccines Focus To Pregnant Women And Unborn Children
The company envisions maternal immunization as a new prong in its strategy to protect a full spectrum of people from disease through vaccinations, ranging from unborn children to senior citizens.